Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 4,225 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions: Varicella Zoster Vaccine, Placebo Injection; Biological · Other
Lead sponsor: Kevin Winthrop; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 5
States / cities: Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Pertussis, Pertussis Immunisation
Interventions: BPZE1, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pleural Disease, Postoperative Pain
Interventions: Bupivacaine injection, Placebo, Monitored Anesthesia Care; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Conditions: Atrophic Scar
Interventions: Allergan Vollure; Device
Lead sponsor: Siperstein Dermatology; Other
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Huntingtons Disease
Interventions: RO7234292, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more

Conditions: Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
Interventions: DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only); Biological
Lead sponsor: Nuravax, Inc.; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: HIV Infections
Interventions: BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more

Conditions: Hallux Valgus
Interventions: TLC590, Naropin®, Normal Saline, Bupivacaine; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more

Conditions: Osteoarthritis
Interventions: SM04690, Placebo; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 36
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Nephritis, Systemic Lupus Erythematosus
Interventions: AMG 811; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 8
States / cities: Phoenix, Arizona • Danbury, Connecticut • Kansas City, Kansas + 5 more

Conditions: Degenerative Disc Disease
Interventions: Intradiscal rhGDF-5, Water for injection; Drug · Other
Lead sponsor: DePuy Spine; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 10
States / cities: Phoenix, Arizona • Santa Monica, California • Durango, Colorado + 7 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions: Dupilumab, Omalizumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more

Conditions: Neoplasms, Pain
Interventions: Lidocaine; Drug
Lead sponsor: San Diego Hospice & Palliative Care; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Heart Failure
Interventions: PB1046 Injection, Placebo Injection; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more

Conditions: Obesity, Impaired Glucose Tolerance
Interventions: exenatide, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 25 Years to 60 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Perennial Allergic Rhinitis (PAR)
Interventions: LY3650150, Placebo, Standard therapy for INCS; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 26
States / cities: Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more

Conditions: Herpes Simplex Type 2
Interventions: HerpV and QS-21, Placebo; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Portland, Oregon • Houston, Texas • Seattle, Washington

Conditions: Anthrax
Interventions: Normal Saline for Injection, MDX1303; Drug · Biological
Lead sponsor: PharmAthene, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pain, Postoperative, Nerve Block, Robotic Surgical Procedures
Interventions: Bupivacain, Ultrasound-guided transversus abdominus plane block, Laparoscopic-guided transversus abdominus plane block; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Dengue
Interventions: YF-17D, TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more

Conditions: Hidradenitis Suppurativa
Interventions: Spesolimab i.v., Spesolimab s.c., Placebo matching Spesolimab i.v., Placebo matching Spesolimab s.c.; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions: Erythropoietin, Sham Comparator; Drug · Other
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 24 Hours to 96 Days
Enrollment: 318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2000
U.S. locations: 9
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more

Search by objective public record fields.

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults

Erector Spinae Plane Block With Bupivacaine for Medical Thoracoscopy

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Vollure for the Correction of Atrophic Facial Scarring

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

Intravenous (IV) Lidocaine for Opioid-refractory Pain

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

Use of Perioperative Pain Blocks In Urological Surgery

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants